Susceptibility of LDL to oxidation is not associated with the presence of coronary heart disease or renal dysfunction in NIDDM patients

Clinica Chimica Acta

Volumn 275, Issue 2, 1998, Pages 163-174

  Leinonen, Janne S ^a,b,c   Rantalaiho, Vappu ^b   Solakivi, Tiina ^b   Koivula, Timo ^b   Wirta, Ole ^b   Pasternack, Amos ^b   Alho, Hannu ^c,d   Lehtimäki, Terho ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Coronary disease; Diabetes; Low density lipoprotein; Non insulin dependent

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; ALBUMINURIA; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION;

EID: 17544404941     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(98)00083-7     Document Type: Article

References (39)

1. [1] Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. J Am Med Assoc 1979;241:2035-8.
2. [2] Pyörälä K, Laakso M, Uusitupa MI. Diabetes and atherosclerosis: an epidemiologic view. Diabetes 1987;3:463-524.
3. [3] Uusitupa MI, Siitonen O, Pyörälä K, et al. The relationship of cardiovascular risk factors to the prevalence of coronary heart disease in newly diagnosed type 2 (non-insulin-dependent) diabetes. Diabetologia 1985;28:653-9.
4. [4] Parthasarathy SD, Steinberg D, Witztum JL. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu Rev Med 1992;43:219-25.
5. [5] Lopes-Virella MF, Klein RL, Virella G. Modification of lipoproteins in diabetes. Diabetes Metab Rev 1996;12:69-90.
6. [6] Steinbrecher UP, Witztum JL. Glucosylation of low density lipoprotein to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984;33:130-4.
7. [7] Ceriello A, Bortolotti N, Falleti E, et al. Total radical-trapping antioxidant parameter in NIDDM patients. Diabetes Care 1997;20:194-7.
8. [8] Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb Vasc Biol 1992;12:1496-502.
9. [9] Keane WF, O'Donnell MP, Kasiske BL, Kim Y. Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol 1992;4:187-94.
10. [10] Korpinen E, Åkerblom HK, Groop P-H, Vaarala O. Immune response to glycated and oxidized LDL in IDDM patients with and without renal disease. Diabetes Care 1997;20:1168-71.
11. [11] Rabini RA, Fumelli P, Galassi R, et al. Increased susceptibility to lipid oxidation of low-density lipoproteins and erythrocyte membranes from diabetic patients. Metabolism 1994;43:1470-4.
12. [12] Yoshida HT, Ishikawa T, Nakamura H. Vitamin E/lipid peroxide ratio and susceptibility of LDL to oxidative modification in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1997;17:1438-46.
13. [13] Leonhardt W, Hanefeld M, Muller G, et al. Impact of concentrations of glycated hemoglobin, alpha-tocopherol, copper, and manganese on oxidation of low-density lipoproteins in patients with type I diabetes, type II diabetes and control subjects. Clin Chim Acta 1996;254:173-86.
14. [14] Dimitriadis E, Griffin M, Owens D, Johnson A, Collins P, Tomkin GH. Oxidation of low-density lipoprotein in NIDDM: its relationship to fatty acid composition. Diabetologia 1995;38:1300-6.
15. [15] Beaudeux JL, Guillausseau PJ, Peynet J, et al. Enhanced susceptibility of low-density lipoprotein to in vitro oxidation in type 1 and type 2 diabetic patients. Clin Chim Acta 1995;239:131-41.
16. [16] Cominacini L, Garbin U, Pastorino AM, et al. Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Diabetes Res 1994;26:173-84.
17. [17] Salonen JT, Ylä-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
18. [18] Bellomo GE, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes 1995;44:60-6.
19. [19] Uusitupa MI, Niskanen LK, Luoma J, et al. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:1236-42.
20. [20] Regnström J, Nilsson J, Per Tornvall VL, Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992;339:1183-6.
21. [21] Wirta OR, Pasternack AI. Glomerular filtration rate and kidney size in type 2 (non-insulindependent) diabetes mellitus. Clin Nephrol 1995;44:1-7.
22. [22] WHO expert committee on diabetes mellitus. The second report: 646. Technical report series 1980. WHO, Geneva.
23. [23] Rose GA, Blackburn H. Cardiovascular survey methods. WHO Monograph Series 1968;56.
24. [24] Warnick GR, Benderson J, Albers JJ. In: Cooper GR, editor. Selected methods of clinical chemistry. American Association for Clinical Chemistry, 1983:91-99.
25. [25] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
26. [26] Catignani G, Bieri J. Simultaneous determination of retinol and alpha-tocopherol in serum or plasma by liquid chromatography. Clin Chem 1983;29:708-12.
27. 51Cr-edetic acid complex. Lancet 1967;1:818.
28. [28] Chung BH, Segrest JP, Ray MJ, et al. Single vertical spin gradient ultracentrifugation. Methods Enzymol 1986;128:181-209.
29. [29] Markwell MAK, Hass SM, Tolbert NE, Bieber LL. Protein determination in membrane and lipoprotein samples: manual and automatic procedures. Methods Enzymol 1981;123:293-303.
30. [30] Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Rad Res Comm 1989;6:67-75.
31. [31] Kleinveld HA, Hak-Lemmers HLM, Stalenhoef AFH, Demacker PNM. Improved measurement of low-density lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density lipoprotein. Clin Chem 1992;38:2066-72.
32. [32] Kobayashi K, Watanabe J, Umeda F, Nawata H. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocrine J 1995;42:461-5.
33. [33] Bowie A, Owens D, Collins P, Johnson A, Tomkin GH. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 1993;102:63-7.
34. [34] Leinonen J, Lehtimäki T, Toyokuni S, et al. New Biomarker evidence of increased oxidative DNA damage in patients with non-insulin-dependent diabetes mellitus. FEBS Lett 1997;417:150-2.
35. [35] Leinonen J, Rantalaiho V, Lehtimaki T et al. The association between the total antioxidant potential of plasma and the occurrence of coronary heart disease and renal dysfunction in patients with NIDDM. Free Rad Res 1998; in press.
36. [36] Sundaram RK, Bhaskar A, Vijayalingam S, Viswanathan M, Mohan R, Shanmugasundaram KR. Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications. Clin Sci 1996;90:255-60.
37. [37] Gallou G, Ruelland A, Legras B, Maugendre D, Allannic H, Cloarec L. Plasma malondialdehyde in type 1 and type 2 diabetic patients. Clin Chim Acta 1993;214:227-34.
38. [38] Velazquez E, Winocour PH, Kesteven P, Alberti KG, Laker MF. Relation of lipid peroxides to macrovascular disease in type 2 diabetes. Diabetes Med 1991;8:752-8.
39. [39] Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997;272:20963-6.